Abstract
Subcutaneous low-dose alemtuzumab (10 mg t.i.w. for 18 weeks) induced a 50% response rate, including 25% complete response, in 16 patients with refractory chronic lymphocytic leukemia (CLL) patients. The responses were substantial even in patients with unfavorable cytogenetics, fludarabine/rituximab refractoriness, Rai stage IV, previous infections, and age over 65 years. Subcutaneous low-dose alemtuzumab is effective in poor prognosis B-CLL, and has a particularly favourable toxicity profile.
| Original language | English |
|---|---|
| Pages (from-to) | 410-412 |
| Number of pages | 3 |
| Journal | Haematologica |
| Volume | 90 |
| Issue number | 3 |
| Publication status | Published - Mar 2005 |
Fingerprint
Keywords
- Alemtuzumab
- Autoimmune hemolytic anemia
- B-CLL
- Complete response
- HBV
- Overall response
- Safety
ASJC Scopus subject areas
- Hematology
Cite this
Cortelezzi, A., Pasquini, M. C., Sarina, B., Bertani, G., Grifoni, F., Colombi, M., & Deliliers, G. L. (2005). A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica, 90(3), 410-412.